BioMarin Pharmaceutical | BMRN - Ebitda

Aktienkurs
55.95
Täglich Wechseln
0.45 0.81%
Monatlich
-4.41%
Jährlich
-17.09%
Q2 Prognose
53.83




Ebitda Veränderung Datum
Acadia Pharmaceuticals USD 35.76M 447K 2025-09
Agios Pharmaceuticals USD -115.49M 10.3M 2025-09
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Bayer EUR 1.97B 457M 2025-12
Biogen USD 573.2M 253.7M 2025-12
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Gilead Sciences USD 4.03B 628M 2025-09
Incyte USD 414.5M 92.42M 2025-12
Insmed USD -314.19M 31.48M 2025-12
Ionis Pharmaceuticals USD -157.12M 307.36M 2025-09
Moderna USD -790M 582M 2025-12
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
PTC Therapeutics USD 20.63M 53.74M 2025-09
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.92B 261.9M 2025-09
Roche Holding CHF 12.68B 2.36B 2024-06
Sanofi EUR 5.66B 3.77B 2025-09
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
Ultragenyx Pharmaceutical USD -156.79M 65.44M 2025-09
United Therapeutics USD 379.5M 83.4M 2025-12
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09